MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2S.-H. Lee, M.E. Marmarelis, Saiama N. Waqar et al.|Journal of Thoracic Oncology|2023Cited by 4
MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLCBenjamin Besse, E. Felip, P. Tomasini et al.|Journal of Thoracic Oncology|2025Cited by 1